Long‐term response to osimertinib in elderly patients with lung adenocarcinoma harbouring de novo EGFR T790M: a case report and literature review

Osimertinib is a potent and irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that selectively acts on both EGFR‐sensitive and EGFR T790M‐resistant mutations. Patients with pre‐treatment EGFR T790M mutations (de novo EGFR T790M) respond poorly to existing EGFR‐TKIs...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Respirol Case Rep
Main Authors: Sumi, Toshiyuki, Kamada, Koki, Shijubou, Naoki, Yamada, Yuichi, Nakata, Hisashi, Mori, Yuji, Chiba, Hirofumi
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Ltd 2021
Assuntos:
Case Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8094050/
https://ncbi.nlm.nih.gov/pubmed/33976888
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/rcr2.759
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados